In addition, some studies found that the aberrant expression and activation of MET result in the activation of the ERBB3/PI3K/AKT pathway, which is associated with the resistance of EGFR inhibitors in lung cancer, and this resistance can be reversed by combining MET inhibitors and EGFR inhibitors. Here, ERBB3 is linked to lung carcinoma.